Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy

Hepatology International

Volumn 4, Issue 3, 2010, Pages 594-600

  Ide, Tatsuya ^a   Sata, Michio ^a   Chayama, Kazuaki ^b   Shindo, Michiko ^c   Toyota, Joji ^d   Mochida, Satoshi ^e   Tomita, Eiichi ^f   Kumada, Hiromitsu ^g   Yamada, Gotaro ^h   Yatsuhashi, Hiroshi ⁱ   Hayashi, Norio ^j   Ishikawa, Hiroki ^k   Seriu, Taku ^k   Omata, Masao ^l  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Akashi Municipal Hospital   (Japan)

^d Sapporo Kosei General Hospital   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f Gifu Municipal Hospital   (Japan)

^g TORANOMON HOSPITAL   (Japan)

^h KAWASAKI MEDICAL SCHOOL   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^j OSAKA UNIVERSITY   (Japan)

^k Research and Development   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

Chronic hepatitis B; Entecavir; Japanese; Lamivudine; Switch

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALLERGIC RHINITIS; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFLUENZA; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENIERE DISEASE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; SKIN ABSCESS; TREATMENT DURATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 77958083205     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9185-3     Document Type: Article

References (30)

1. D Lavanchy 2005 Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention J Clin Virol 34 Suppl 1 S1 S3 10.1016/S1386-6532(05) 00384-7 16461208 (Pubitemid 43197742)
2. I Merican R Guan D Amarapuka MJ Alexander A Chutaputti RN Chien, et al. 2000 Chronic hepatitis B virus infection in Asian countries J Gastroenterol Hepatol 15 1356 1361 1:STN:280:DC%2BD3M7jvFCitw%3D%3D 10.1046/j.1440-1746.2000. 0150121356.x 11197043 (Pubitemid 32052906)
3. G Fattovich F Bortolotti F Donato 2008 Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 335 352 10.1016/j.jhep.2007.11.011 18096267
4. CL Lai RN Chien NW Leung TT Chang R Guan DI Tai, et al. 1998 A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group N Engl J Med 339 61 68 1:CAS:528:DyaK1cXkvVSqtbY%3D 10.1056/ NEJM199807093390201 9654535 (Pubitemid 28304879)
5. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman, et al. 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256 1263 1:CAS:528:DyaK1MXnt1Cqs78%3D 10.1056/NEJM199910213411702 10528035 (Pubitemid 29489740)
6. AS Lok CL Lai N Leung GB Yao ZY Cui ER Schiff, et al. 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722 1:CAS:528:DC%2BD2cXhtVOrug%3D%3D 10.1053/j.gastro.2003.09.033 14724824 (Pubitemid 37500436)
7. SF Innaimo M Seifer GS Bisacchi DN Standring R Zahler RJ Colonno 1997 Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus Antimicrob Agents Chemother 41 1444 1448 1:CAS:528:DyaK2sXktlyrtbs%3D 9210663
8. TT Chang RG Gish R de Man A Gadano J Sollano YC Chao, et al. 2006 A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 1001 1010 1:CAS:528:DC%2BD28XitFWms7Y%3D 10.1056/NEJMoa051285 16525137 (Pubitemid 43357804)
9. CL Lai D Shouval AS Lok TT Chang H Cheinquer Z Goodman, et al. 2006 Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 1011 1020 1:CAS:528:DC%2BD28XitFWlsrY%3D 10.1056/NEJMoa051287 16525138 (Pubitemid 43357805)
10. M Sherman C Yurdaydin J Sollano M Silva YF Liaw J Cianciara, et al. 2006 Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 130 2039 2049 1:CAS:528:DC%2BD28XntVWitrw%3D 10.1053/j.gastro.2006.04.007 16762627 (Pubitemid 43816960)
11. M Shindo K Chayama H Kumada O Yokosuka M Sata N Hayashi, et al. 2009 Investigation of the antiviral activity, dose-response relationship and safety of entecavir following 24-week oral dosing in nucleoside-naive adult patients with chronic hepatitis B: a randomized double-blind Phase II clinical trial in Japanese patients Hepatol Int 3 445 452 10.1007/s12072-009-9135-0
12. DJ Tenney RE Rose CJ Baldick KA Pokornowski BJ Eggers J Fang, et al. 2009 Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 1503 1514 1:CAS:528:DC%2BD1MXlslKmurw%3D 10.1002/hep.22841 19280622
13. Kumada H. Report of the research for therapy standardization of viral hepatitis including liver cirrhosis. The Research on Hepatitis, Health and Labor Science Research Grants: revised edition; 2010
14. AS Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 1:CAS:528:DC%2BD2sXisVKns7o%3D 10.1002/hep.21513 17256718 (Pubitemid 46374607)
15. European Association for the Study of the Liver 2009 EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
16. YF Liaw N Leung JH Kao T Piratvisuth E Gane KH Han, et al. 2009 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 10.1007/s12072-008-9080-3
17. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010 (in press)
18. SH Han TT Chang YC Chao S Yoon RG Gish H Cheinquer, et al. 2008 Five years of continuous entecavir for nucleoside-naive HBeAg(+) chronic hepatitis B: results from study ETV-901 Hepatology 48 Suppl 1 705A 706A
19. D Shouval CL Lai TT Chang A Gadano SS Wu W Halota, et al. 2008 Three years of entecavir re-treatment of HBeAg(-) entecavir patients who previously discontinued entecavir therapy: results from study ETV-901 Hepatology 48 Suppl 1 722A 723A
20. O Yokosuka H Kumada J Toyota K Takaguchi H Kobashi M Shindo, et al. 2008 Three-year assessment of entecavir resistance in nucleoside-naïve and lamivudine-refractory Japanese patients with chronic hepatitis B Hepatol Int 2 A161
21. YF Liaw TT Chang SS Wu ER Schiff KH Han CL Lai, et al. 2008 Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901 Hepatology 48 Suppl 1 706A
22. N Izumi H Kumada J Toyota O Yokosuka H Kobashi M Shindo, et al. 2008 Efficacy and safety of 3 years treatment with entecavir in lamivudine-refractory Japanese chronic hepatitis B patients Hepatol Int 2 A186
23. F Suzuki J Toyoda Y Katano M Sata M Moriyama F Imazeki, et al. 2008 Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients J Gastroenterol Hepatol 23 1320 1326 1:CAS:528:DC%2BD1cXht1Cls7jL 10.1111/j.1440-1746.2008. 05455.x 18554238
24. M Sherman C Yurdaydin H Simsek M Silva YF Liaw VK Rustgi, et al. 2008 Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks Hepatology 48 99 108 1:CAS:528:DC%2BD1cXptFemtbc%3D 10.1002/hep.22323 18537189 (Pubitemid 351975535)
25. MG Peters HH Hann P Martin EJ Heathcote P Buggisch R Rubin, et al. 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 91 101 1:CAS:528:DC%2BD2cXhtFGntLo%3D 10.1053/j.gastro.2003.10.051 14699491 (Pubitemid 38040727)
26. I Rapti E Dimou P Mitsoula SJ Hadziyannis 2007 Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B Hepatology 45 307 313 1:CAS:528:DC%2BD2sXisVKgu70%3D 10.1002/hep.21534 17256746 (Pubitemid 46374587)
27. Lampertico P, Marzano A, Levrero M, Santantonio T, Di M, V, Brunetto M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. J Hepatol 2008;46 Suppl 1:S191
28. P Marcellin EJ Heathcote M Buti E Gane RA de Man Z Krastev, et al. 2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2442 2455 1:CAS:528:DC%2BD1cXhsVCrurjL 10.1056/NEJMoa0802878 19052126
29. F van Bommel RA de Man H Wedemeyer K Deterding J Petersen P Buggisch, et al. 2010 Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 73 80 19998272
30. WF Leemans HJ Flink HL Janssen HG Niesters SW Schalm RA de Man 2006 The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection J Hepatol 44 507 511 1:CAS:528:DC%2BD28XhsFKksbY%3D 10.1016/j.jhep.2005.12.004 16457904 (Pubitemid 43227874)